17 results about "Quinine" patented technology

This invention discloses a rapid mass spectrometry method and kit for the simultaneous detection of multiple components in body fluids, belonging to the field of biological detection and identification technology. It can rapidly detect trace compounds such as drugs and biomarkers in complex biological samples. This kit mainly utilizes loaded functional materials to achieve extraction and enrichment of target analytes and is equipped with a quick connector for coupling with a detector to achieve rapid detection. Compared with traditional methods, the significant advantages of the method established by this kit are that it does not require complex sample pretreatment, allows for micro-quantitative sampling, requires small sample volumes, facilitates convenient storage of biological samples, is easy to operate, does not require specialized technical personnel, and enables rapid on-site detection when coupled with portable mass spectrometry. This kit has been successfully used for the detection of quinine, procainamide hydrochloride, atenolol, and nortriptyline in complex samples such as blood and serum, and has significant clinical and economic value.

The invention discloses application of a small molecule compound in targeting TOPBP1 protein, and belongs to the technical field of biological medicine. The application verifies that various small molecular compounds, namely diclofenac sodium, zaltoprofen, quinine and adamantine acetic acid, can be combined with the BRCT 7-8 structural domain of the TOPBP1, so as to target the TOPBP1 protein, and the dissociation equilibrium constant of the combination is between 100 and 250 mu M. And through AI model prediction, X-ray crystallography technology and the like, the combined action mechanism is disclosed. The application proves that diclofenac sodium, zaltoprofen, quinine and adamantane acetic acid as a class of small molecular compounds have the potential of serving as candidate molecules of antitumor drugs.

The invention belongs to the technical field of biology, and provides a paracoccus Wheatstone strain and application thereof, the paracoccus Wheatstone strain can produce pyrroloquinoline quinine at high yield, the strain is named as YJY25-02, and the preservation number is CGMCC NO.34258. The strain is subjected to shake-flask aerobic culture for 83h, and the titer of the pyrroloquinoline quinone in fermentation liquor is 176.7 mg / L; the titer of pyrroloquinoline quinine in fermentation liquor during aerobic culture in a fermentation tank is 1796-1863 mg / L, the methanol conversion rate is 16.19-18.12 mg / g, the method has the advantages of short fermentation time, high titer and high methanol conversion rate, and the problem of large-scale production can be solved; pure pyrroloquinoline quinine with the purity larger than or equal to 98% is prepared through separation and purification of fermentation liquor, the yield ranges from 80% to 85%, the high yield and high purity of the pure pyrroloquinoline quinine are achieved, the separation and purification process is simple, the cost is low, organic solvents difficult to remove are not introduced, and the safety of the product is guaranteed.

The invention discloses a separation, analysis and determination method of aztreonam and enantiomers thereof, and belongs to the technical field of pharmaceutical analysis. According to the method, silica gel surface covalently bonded O-9-(tert-butyl carbamoyl) quinine is adopted as a filler (QN-AX, 4.6 mm * 150mm, 5 [mu] m), and methanol / acetonitrile / acetic acid / triethylamine = 50 / 50 / 2 / 1.6 (v / v / v / v) is adopted as a mobile phase for isocratic elution. The method can simply, accurately and efficiently analyze and detect aztreonam and the enantiomer thereof, and effectively control the quality of aztreonam and the enantiomer thereof.

The application provides application of a TAS2R4 agonist in preparation of a drug for treating and preventing diabetic nephropathy, and comprises that a bitter taste receptor 4 subtype (TAS2R4) can be used as a drug target point for treating and preventing diabetic nephropathy, and quinine is used as a TAS2R4 agonist. Specifically, mouse diabetic nephropathy induced by a chemical reagent and mouse podocyte cell line MPC cell damage caused by chronic high glucose are taken as research objects, it is found that mouse TAS2R4 agonist quinine has a prevention and treatment effect on diabetic nephropathy, has a protection effect on podocyte loss caused by high glucose, and has an activation effect on mouse kidney TAS2R4 molecular signal, and a possible molecular mechanism is discussed from the aspects of inhibiting NLRP3 inflammasome activation and NF-kappa B signal activation path, and theoretical basis and technical support are provided for prevention and treatment of diabetic nephropathy, other kidney diseases with inactivation of TAS2R4 molecular signal and other diseases by using TAS2R4 agonists including quinine.

This invention discloses a method for determining the bitterness of hydrolyzed milk protein and its application. The method includes: (1) enzymatically hydrolyzing casein samples using a neutral protease suitable for reaction at 40-55℃. (2) after enzymatic hydrolysis, inactivating the enzyme, centrifuging the hydrolyzed sample, and taking the supernatant for descriptive sensory evaluation; simultaneously, sensory evaluation of a series of quinine solutions with different concentration gradients is performed to obtain their bitterness values. (3) by correlating samples with different degrees of hydrolysis and different concentrations of quinine through sensory scoring, a functional relationship curve is constructed, and the corresponding mathematical model is obtained. (4) by comparing samples with different degrees of hydrolysis and quinine solutions with different concentration ranges, the quinine concentration corresponding to a quinine selectivity of 50% is obtained, and the quinine concentration-intensity curve of the enzymatically hydrolyzed samples under different degrees of hydrolysis is obtained, so that the quinine equivalent value of samples with different degrees of hydrolysis can be calculated. Therefore, this invention provides ideas and methods for solving the problem that bitterness in dairy products is difficult to quantitatively describe and predict.

The invention relates to the technical field of eutecticevaporate solvents, in particular to application of a hydroxyl hydrophobic eutecticevaporate solvent in quinine extraction. The method comprises the following steps: placing a hydroxyl hydrophobic deep-eutectic solvent in a quinine-containing aqueous solution, and extracting quinine under the conditions of constant temperature and stirring; the structural formula of the hydroxyl hydrophobic deep-eutectic solvent is shown in the specification. The hydroxyl hydrophobic eutecticevaporate solvent prepared by the preparation method disclosed by the invention has relatively strong trapping capability on quinine; meanwhile, the eutectic solvent has good phase forming ability, and phase separation can be achieved with a small dosage. Under the conditions that the volume ratio of the hydroxyl hydrophobic deep-eutectic solvent to the quinine aqueous solution is 1: 80 and the pH value is 10, the recovery efficiency of quinine is as high as 97.73%. The hydroxyl hydrophobic deep-eutectic solvent extraction agent is high in separation efficiency, environmentally friendly and low in price. # imgabs0 #

The application provides application of quinofine or a synthetic bacterium thereof in treatment of diseases related to mutation of tyrosyl-tRNA synthetase. The quinofine or the synthetic bacterium thereof can restore defects caused by mutation of tyrosyl-tRNA synthetase, and thus can be used for treatment of diseases related to mutation of human tyrosyl-tRNA synthetase, such as Charcot-Marie-Tooth disease type C and infantile onset multi-system neurologic, endocrine and pancreatic disease type 2, or reproduction defects of Caenorhabditis elegans.

Pharmaceutical compositions comprising active doses of EGCG or a combination of EGCG and quinine or EGCG and a zinc salt for topical treatment of dysplastic or neoplastic cells in mucosal or cutaneous epithelial cells, including cervical intra-epithelial neoplasia, and methods for their use to induce regression of mucosal dysplasia are provided.

The present invention belongs to the field of plant antimicrobial agents, specifically relating to a quinine hydrazone derivative, its preparation method, and application. The quinine hydrazone derivative has a general structural formula as shown in Formula I. Antimicrobial experiments have demonstrated that the quinine hydrazone derivative provided by the present invention exhibits significant antibacterial activity against plant pathogenic fungi / oomycetes. Some compounds exhibit antibacterial activity exceeding that of currently marketed antimicrobial agents triadimefon / metalaxyl, and can be used to prepare botanical fungicides.

The invention belongs to the technical field of microbial fermentation, and discloses a method for producing pyrroloquinoline quinine by utilizing tanshinone to induce hyphomicrobe fermentation, which comprises the following steps of: screening hyphomicrobe by utilizing a selective culture medium containing 0.01 mg / L of tanshinone to obtain a tolerant strain, and respectively adding 0.1 mg / L of tanshinone mother liquor in 12, 24, 36, 48 and 60 hours of fermentation during fermentation culture, the fermentation conditions are regulated and controlled until the final concentration is 0.01 mg / L, so that the yield of the pyrroloquinoline quinine is remarkably improved.

The invention provides a method for preparing pyrroloquinoline quinine-loaded nano-microspheres by using a PQQ-containing aqueous solution and application of the pyrroloquinoline quinine-loaded nano-microspheres. The method comprises the steps of enrichment of a PQQ-containing solution, preparation of an ultrasonic emulsion, preparation of the nano-microspheres and the like, and the PQQ nano-microspheres are obtained. The PQQ nano-microsphere disclosed by the invention has relatively high stability, slow release property and bioavailability, and can effectively solve the problems of low solubility and non-uniform distribution of PQQ in water. The PQQ nano-microspheres are added into the fertilizer as an auxiliary material, so that the soil bulk density can be reduced, the soil porosity can be increased, the soil property can be improved, the crop growth and development can be promoted, and the crop yield can be increased. The PQQ nano-microsphere can be suitable for different types of fertilizers and crops, has a wide application prospect, and provides powerful support for agricultural production.

The present invention provides a novel salt of (S)-quinuclidin-3-yl ((R)-5-(3-chloro-4-isopropoxyphenyl)-2, 2-dimethyl-2, 3-dihydro-1H-inden-1-yl) carbamate, i.e., a (1S)-(+)-10-camphorsulfonate salt thereof, and a method for preparing the same, in particular, a novel salt of (S)-quinuclidin-3-yl ((R)-5-(3-chloro-4-isopropoxyphenyl)-2, 2-dimethyl-2, 3-dihydro-1H-inden-1-yl) carbamate. According to the present invention, the (1S)-(+)-10-camphorsulfonate salt of (S)-quinuclidin-3-yl ((R)-5-(3-chloro-4-isopropoxyphenyl)-2, 2-dimethyl-2, 3-dihydro-1H-inden-1-yl) carbamate is obtained in a crystalline form, which has high purity, high stability, high water solubility and low hygroscopicity, as well as a process for the preparation of the (S)-quinuclidin-3-yl ((R)-5-(3-chloro-4-isopropoxyphenyl)-2, 2-dimethyl-2, 3-dihydro-1H-inden-1-yl) carbamate.

The utility model discloses an extraction separation device which comprises an extraction separation box, the upper end of the extraction separation box is fixedly connected with a first feed port and a second feed port in a penetrating mode, one side of the extraction separation box is provided with a first collection box, one side of the first collection box is connected with a water pipe in a penetrating mode, and one side of the water pipe is fixedly connected with a water valve in a penetrating mode. A stirring box is arranged in the extraction separation box, a plurality of stirring rods are arranged in the stirring box, and a standing box and a second collecting box are arranged in the extraction separation box. Through the structure, an extraction agent and pyrroloquinoline quinine enter from the first feed port and the second feed port respectively, are stirred by the plurality of stirring rods to be fully mixed, and are stood in the standing box, the second baffle is arranged in the standing box, and after standing is completed, the extraction agent and pyrroloquinoline quinine can be separated by the second baffle, so that the extraction agent and the pyrroloquinoline quinine are separated from each other, and the extraction agent and the pyrroloquinoline quinine are separated from each other. The pyrroloquinoline quinine can fall into the second collecting box, so that the pyrroloquinoline quinine can be taken out more conveniently.

The present invention relates to the field of medicinal chemistry, and more particularly to a method for preparing quinine. The method involves introducing two chiral centers in a one-step reaction using a transition metal catalyst, has high selectivity, simplifies the process, and produces a high-purity product with a high yield, facilitating industrial production.

Described are processes for the manufacture of compounds containing a (S)-4,5-dihydro-1H-pyrazole ring. These processes include a chiral resolution step of an intermediate using selected chiral resolving agents. For example, the chiral resolving agents may be selected from (−)-quinine, (R)-phenethylamine, (S)-phenethylamine, (S)-1-naphthylethylamine, (R)-(−)-2-amino-3-methyl-1-butanol, (−)-cinchonidine, (−)-spartein, (R)-1-naphthylethylamine, D-arginine, L-lysine, (S)-(+)-2-pyrrolidinemethanol and (1R,2S)-(+)-cis-1-amino-2-indanol.

The invention provides application of pyrroloquinoline quinine or pyrroloquinoline quinine salt in preparation of a product for treating and / or improving the ovulation function of polycystic ovarian syndrome and improving fertility. Through the product, the ovarian polycystic form of a PCOS patient can be improved, sex hormone secretion disorder can be improved, the estrus cycle can be adjusted, ovarian fibrosis can be improved, oocyte maturation can be promoted, early embryonic development potential can be improved, and pregnancy can be promoted.